Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.

Abstract

Innovative therapeutic approaches based on risk-adapted, patient-oriented approaches would be possible in this AML subtype, provided that answers to many unresolved questions are given.